Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (674)	10/29/1999 10:53:00 AM
From: Jarrod W. Pakosh	Read Replies (1) \| Respond to of 783

You make total sense Jim. My problem is that I HAVE been long on BCH. I've owned the stock for more than 10 years now and I'm getting a little impatient that's all. I think it was 2 years ago the stock hit $40.00 ($80.00 at that time) and I felt it would skyrocket so I held. With all that's happened in those two years, it's just frustrating seeing it stuck at $30.00. I obviously believe in Biochem, it's management and it's potential. I'm just getting a little disillusioned that other investors don't see it just yet. Too many shares in my opinion but it's a great stock! Jarrod P.S. Thank Jim, you did convince me to hold on a little longer!

To: Jim Oravetz who wrote (674)	10/29/1999 10:57:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 783

1)LAVAL, QC -- Jan. 8, 1999 -- Glaxo Wellcome's Heptodin (lamivudine) has been approved in China for the oral antiviral treatment of chronic hepatitis B. Heptodin is one of the first Western medicines to be granted a Class 1 drug certificate in China, which offers the advantage of manufacturing exclusivity for the product in the treatment of hepatitis B for a period of eight years. 2) LAVAL, QC -- May 26, 1999 -- Glaxo Wellcome's (and BCHE) Zeffix (lamivudine), the world's first oral antiviral treatment of chronic hepatitis B, is approved in South Korea. 3)April 10,1997 These results indicate that over a one year period, improvements in liver histology were demonstrated in a significantly higher percentage of lamivudine patients compared to placebo (67% of patients receiving lamivudine 100 mg orally once daily and 59% of patients receiving lamivudine 25 mg orally once daily, compared to 30% of patients receiving placebo). In addition, fewer lamivudine patients (7% of patients on 100 mg and 10% of patients on 25 mg) had deterioration of liver histology compared to placebo (32%)...... .....The presence of hepatitis B e antigen (HBeAg) in patients with hepatitis B is associated with active viral replication. The study results indicate that 16% of patients on lamivudine 100 mg compared to 4% of patients on placebo converted from being HBeAg positive to HBeAg negative with undetectable hepatitis B virus (HBV) DNA. This response, known as seroconversion, is indicative of the body's immune system mounting an effective response to this viral protein...... pslgroup.com Jim

To: Jim Oravetz who wrote (674)	12/1/1999 11:40:00 AM
From: tuck	Read Replies (1) \| Respond to of 783

Jim et. al., BCHE has finished presenting at RS conference. Considering the general post conference sell off happening in many of the presenting stocks, BCHE seems to be holding up OK. Wednesday, December 1, 1999 Grand Ballroom Wedgwood Room Regency Room Cotillion Room 7:30 a.m. Registration and Continental Breakfast — Garden Foyer 8:00 a.m. COR Therapeutics a,b Versicor Cimtek Commerce ResMed 8:30 a.m. Boston Scientific OnHealth Network ACTELION Progenics a,b 9:00 a.m. Health Management ChannelPoint AeroGen TRANSGENE a,b 9:30 a.m. Ares-Serono Axys Pharmaceuticals a Phase Forward QIAGEN 10:00 a.m. BioChem Pharma a INSMED Eurand MedQuist a,b 10:30 a.m. Chemdex a,b Neurocrine Biosciences a Rigel ArthroCare a,b 11:00 a.m. Celltech Chiroscience DepoMed The Medicines Co. Trimeris a,b 1:30 p.m. Forest Laboratories Vical Eclipsys a,b LifePoint Hospitals 2:00 p.m. eBenX Aurora Biosciences a,b Pain Therapeutics Biomatrix 2:30 p.m. Miravant Medical a Confer Software GPC Genome Pharma. H. Lundbeck 3:00 p.m. Abgenix a,b Medical Tech. Overview Molecular Circuitry Anesta a,b Wade King, M.D. 3:30 p.m. Genzyme Ethypharm Pharma Mar Axolotl/AccentHealth Cheers, Tuck